Esophageal Squamous Cell Carcinoma

The combination of cabozantinib and atezolizumab has an acceptable safety profile and moderate antitumor activity as a second-line treatment for patients with R/M ESCC.

P1, N=30, Recruiting, Vanderbilt-Ingram Cancer Center | Not yet recruiting --> Recruiting

Cela inhibits ESCC invasion and metastasis via TFRC/HMOX1-mediated ferroptosis, with multi-omics providing systematic mechanistic insights. This study uncovers a novel ferroptosis-centred anti-ESCC mechanism, supporting Cela's therapeutic potential.

We identified a pivotal oncogenic super-enhancer-driven lncRNA, MIR205HG, which interacts with PTBP3 to promote glycolysis in ESCC. It may serve as a promising prognostic biomarker and therapeutic target for patients.

P=N/A, N=88, Not yet recruiting, Fudan University

The PI3K inhibitor LY294002 reversed these pro-tumor and immunosuppressive effects. High COQ10B expression is closely associated with ESCC progression and poor prognosis. These malignant biological behaviors and the associated immunosuppressive tumor microenvironment are potentially mediated via the activation of the PI3K/AKT/HIF-1A signaling pathway.

These findings establish a mechanistic link between microRNA-130b-3p and immune checkpoint activation through IL-33 signaling. The study identifies IL-33 as an independent prognostic marker and a key driver of PD-L1 expression, providing a basis for dual-targeted therapeutic strategies.

Pharmacological blockade of the CKS1B-IRF3 interaction with 14i restores CD8+ T cell function and synergizes with immune checkpoint blockade. The tumor-intrinsic oncogenic-immune axis, which connects cancer cell signaling to immune dysfunction, is conserved across multiple malignancies, establishing a conceptual and therapeutic framework for overcoming tumor-driven T cell exhaustion.

P1/2, N=42, Not yet recruiting, AstraZeneca AB

In vitro, ESCC cell lines (TE13 and Eca9706) were co-treated with DNA-dependent protein kinase catalytic subunit (DNA-PKcs) inhibitors (AZD7648 or NU7741) or PRKDC-targeting siRNA plus irradiation...Our study reveals a novel mechanism by which DNA-PKcs inhibition augments radiosensitivity in ESCC. Targeting DNA-PKcs could represent a promising strategy to improve the efficacy of radiotherapy in ESCC, offering a potential therapeutic approach to overcome radioresistance.

TCGA-based validation showed that only a subset of predicted interactions is functionally relevant, with hsa-miR-30d-5p exhibiting a significant inverse correlation with CHST2. These findings highlight the importance of integrating predictive and expression data to identify biologically meaningful miRNA-mRNA interactions in esophageal cancer.

P=N/A, N=30, Enrolling by invitation, Shanghai Chest Hospital